The effect of ivacaftor in adolescents with cystic fibrosis (G551D mutation): an exercise physiology perspective
- PMID: 25251804
- DOI: 10.1097/PEP.0000000000000086
The effect of ivacaftor in adolescents with cystic fibrosis (G551D mutation): an exercise physiology perspective
Abstract
Purpose: The purpose of this report was to evaluate the influence of 12 weeks of ivacaftor treatment on the aerobic function of 2 teenage patients with cystic fibrosis (CF; ΔF508/G551D) using a maximal cardiopulmonary exercise test.
Summary of key points: One patient, with relatively mild disease, demonstrated no clinically meaningful changes in maximal oxygen uptake ((Equation is included in full-text article.)O2max). However, in the second case, with more established lung disease on imaging, (Equation is included in full-text article.)O2max improved by approximately 30%, an improvement out of proportion with early lung function changes. This improvement resulted from increased muscle oxygen delivery and extraction.
Statement of conclusions: Cardiopulmonary exercise testing can monitor the extent and cause(s) of change following interventions such as ivacaftor, with the potential to identify functional changes independent from spirometry indices.
Recommendations for clinical practice: Cardiopulmonary exercise testing represents an important and comprehensive clinical assessment tool, and its use as an outcome measure in the functional assessment of patients with CF is encouraged.
Similar articles
-
Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment.Clin Sci (Lond). 2017 Jul 16;131(15):2037-2045. doi: 10.1042/CS20170995. Print 2017 Aug 1. Clin Sci (Lond). 2017. PMID: 28611235 Clinical Trial.
-
Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.Lancet Respir Med. 2013 Oct;1(8):630-638. doi: 10.1016/S2213-2600(13)70182-6. Epub 2013 Sep 10. Lancet Respir Med. 2013. PMID: 24461666 Clinical Trial.
-
Ivacaftor for patients with cystic fibrosis.Expert Rev Respir Med. 2014 Oct;8(5):533-8. doi: 10.1586/17476348.2014.951333. Epub 2014 Aug 22. Expert Rev Respir Med. 2014. PMID: 25148205 Review.
-
Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor.Dig Dis Sci. 2016 Jan;61(1):198-207. doi: 10.1007/s10620-015-3834-2. Epub 2015 Aug 7. Dig Dis Sci. 2016. PMID: 26250833 Clinical Trial.
-
Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.Ann Pharmacother. 2012 Jul-Aug;46(7-8):1065-75. doi: 10.1345/aph.1R076. Epub 2012 Jun 26. Ann Pharmacother. 2012. PMID: 22739718 Review.
Cited by
-
Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor/tezacaftor/ivacaftor.Front Sports Act Living. 2024 Feb 23;6:1284878. doi: 10.3389/fspor.2024.1284878. eCollection 2024. Front Sports Act Living. 2024. PMID: 38463712 Free PMC article.
-
One year effect of tezacaftor and ivacaftor on functional exercise capacity and muscle strength in people with cystic fibrosis.Heliyon. 2024 Feb 20;10(5):e26729. doi: 10.1016/j.heliyon.2024.e26729. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38434346 Free PMC article.
-
Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis.Pharmaceuticals (Basel). 2023 Mar 8;16(3):410. doi: 10.3390/ph16030410. Pharmaceuticals (Basel). 2023. PMID: 36986509 Free PMC article. Review.
-
Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis.Pediatr Pulmonol. 2022 Nov;57(11):2652-2658. doi: 10.1002/ppul.26078. Epub 2022 Jul 22. Pediatr Pulmonol. 2022. PMID: 35851858 Free PMC article.
-
Toward the Establishment of New Clinical Endpoints for Cystic Fibrosis: The Role of Lung Clearance Index and Cardiopulmonary Exercise Testing.Front Pediatr. 2021 Feb 25;9:635719. doi: 10.3389/fped.2021.635719. eCollection 2021. Front Pediatr. 2021. PMID: 33718306 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
